Alector Leadership

Rosenthal received his Ph.D. from the Hebrew University Jerusalem, Israel. He was appointed to a scientist at Genentech Inc. in 1988, was promoted to a senior scientist in 1992 and then to a VP level, executive staff scientist and a permanent member of Genentech Research Review Committee in 1996 were he Initiated the research program that led to the development and approval of Erivedge® (vismodegib)‎.In 2001 Dr. Rosenthal co-founded and became the president, board member and CSO of Rinat Neuroscience, a privately held company that discovered novel medicines for neurodegenerative, and pain disorders. The company was acquired by Pfizer in 2006 for ~$500M with several clinical drugs including Tanezumab; Phase III for multiple pain indications, Ajovey approved for migraine, Bococizumab approved for cardiovascular disorders, RN6G; Phase II for dry macular degeneration; Ponezumab; Phase II for Alzheimer’s disease.Rosenthal is a co founder, former CEO and board chair of Annexon bio. The company is in the clinic with novel complement based therapy for neurodegenerative disease http://annexonbio.comDr, Rosenthal is a co-founder president and current CEO of Alector LLC, a public Biotechnology company NASDAQ: ALEC focused on the discovery and envelopment of novel microglia immune checkpoint therapy for Alzheimer's disease and other forms of dementia. http://alector.comRosenthal was a visiting professor at the Department of Anatomy UCSF and is a member of the scientific advisory boards of Simons Foundation Autism Research and of the Myelin Repair Foundation. He has co-authored 108 scientific publications, and over 380 issued patents and applications.https://en.m.wikipedia.org/wiki/Arnon_Rosenthal

Robert King is a Chief Development Officer at Alector and is based in South San Francisco. He has worked as Scientist at Scios; Senior VP:Product Dev at SCICLONE PHARMACEUTICALS INC; and Director, Technical Operations at COR Therapeutics Inc. Robert studied at University of California Berkeley between 1983 and 1988, University of Washington between 1979 and 1983, and Nathan Hale School.

Rosenthal received his Ph.D. from the Hebrew University Jerusalem, Israel. He was appointed to a scientist at Genentech Inc. in 1988, was promoted to a senior scientist in 1992 and then to a VP level, executive staff scientist and a permanent member of Genentech Research Review Committee in 1996 were he Initiated the research program that led to the development and approval of Erivedge® (vismodegib)‎.In 2001 Dr. Rosenthal co-founded and became the president, board member and CSO of Rinat Neuroscience, a privately held company that discovered novel medicines for neurodegenerative, and pain disorders. The company was acquired by Pfizer in 2006 for ~$500M with several clinical drugs including Tanezumab; Phase III for multiple pain indications, Ajovey approved for migraine, Bococizumab approved for cardiovascular disorders, RN6G; Phase II for dry macular degeneration; Ponezumab; Phase II for Alzheimer’s disease.Rosenthal is a co founder, former CEO and board chair of Annexon bio. The company is in the clinic with novel complement based therapy for neurodegenerative disease http://annexonbio.comDr, Rosenthal is a co-founder president and current CEO of Alector LLC, a public Biotechnology company NASDAQ: ALEC focused on the discovery and envelopment of novel microglia immune checkpoint therapy for Alzheimer's disease and other forms of dementia. http://alector.comRosenthal was a visiting professor at the Department of Anatomy UCSF and is a member of the scientific advisory boards of Simons Foundation Autism Research and of the Myelin Repair Foundation. He has co-authored 108 scientific publications, and over 380 issued patents and applications.https://en.m.wikipedia.org/wiki/Arnon_Rosenthal

Rosenthal received his Ph.D. from the Hebrew University Jerusalem, Israel. He was appointed to a scientist at Genentech Inc. in 1988, was promoted to a senior scientist in 1992 and then to a VP level, executive staff scientist and a permanent member of Genentech Research Review Committee in 1996 were he Initiated the research program that led to the development and approval of Erivedge® (vismodegib)‎.In 2001 Dr. Rosenthal co-founded and became the president, board member and CSO of Rinat Neuroscience, a privately held company that discovered novel medicines for neurodegenerative, and pain disorders. The company was acquired by Pfizer in 2006 for ~$500M with several clinical drugs including Tanezumab; Phase III for multiple pain indications, Ajovey approved for migraine, Bococizumab approved for cardiovascular disorders, RN6G; Phase II for dry macular degeneration; Ponezumab; Phase II for Alzheimer’s disease.Rosenthal is a co founder, former CEO and board chair of Annexon bio. The company is in the clinic with novel complement based therapy for neurodegenerative disease http://annexonbio.comDr, Rosenthal is a co-founder president and current CEO of Alector LLC, a public Biotechnology company NASDAQ: ALEC focused on the discovery and envelopment of novel microglia immune checkpoint therapy for Alzheimer's disease and other forms of dementia. http://alector.comRosenthal was a visiting professor at the Department of Anatomy UCSF and is a member of the scientific advisory boards of Simons Foundation Autism Research and of the Myelin Repair Foundation. He has co-authored 108 scientific publications, and over 380 issued patents and applications.https://en.m.wikipedia.org/wiki/Arnon_Rosenthal